Arrakis Therapeutics Inc. is in the middle of a big pivot from building its platform for the discovery of small molecules that target RNA to generating a pipeline of drug candidates – and now it has $75m in Series B venture capital funding to expand its compound library and advance its first programs into the clinic.
The Waltham, Mass.-based company also now has a permanent CEO since Michael Gilman, who has been splitting his time between...






